Home » News » Clinical Intelligence » Jennerex enrolls first patient in phase IIb liver cancer trial

Jennerex enrolls first patient in phase IIb liver cancer trial

Friday, November 4, 2011

Jennerex has initiated enrollment and the first patient has
been randomized in a phase IIb clinical trial called TRAVERSE.  The trial
is evaluating the use of JX-594 to treat patients with advanced liver
cancer, also known as hepatocellular carcinoma (HCC), who failed prior
therapy with sorafenib (NexavarR), the only approved drug for advanced
HCC.  In addition, Jennerex earned a milestone payment from its
development and commercialization partner, Transgene, based on the
randomization of the first patient in the TRAVERSE clinical trial.

The TRAVERSE phase IIb clinical trial is designed to enroll 120 patients
with advanced liver cancer who have failed sorafenib therapy. The
randomized study will be conducted at approximately 45 sites worldwide
including North America, South Korea, Taiwan, Hong Kong, and Europe. The
primary objective of the trial is to determine the overall survival
benefit for patients receiving JX-594 with best supportive care, compared
to best supportive care alone in patients with refractory advanced liver

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!